UPMC: Immunotherapy Trial Informs Treatment of Advanced Skin Cancer
May 31, 2025
May 31, 2025
PITTSBURGH, Pennsylvania, May 31 (TNSjou) -- The University of Pittsburgh Medical Center issued the following news release:
* * *
Immunotherapy Trial Informs Treatment of Advanced Skin Cancer
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared t . . .
* * *
Immunotherapy Trial Informs Treatment of Advanced Skin Cancer
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared t . . .